AbbVie Inc. buy Saftman
Start price
08.07.21
/
50%
€98.99
Target price
08.07.22
-
Performance (%)
50.06%
End price
08.07.22
€148.54
Summary
This prediction ended on 08.07.22 with a price of €148.54. The BUY prediction by Saftman for AbbVie Inc. saw massive gains of 50.06%. A total of €4.75 was paid as dividends for this prediction. Saftman has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| AbbVie Inc. | 1.924% | 1.924% | 5.545% |
| iShares Core DAX® | 1.804% | -0.748% | 13.168% |
| iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% |
| iShares Nikkei 225® | 0.413% | -7.381% | 18.776% |
| iShares S&P 500 | 0.664% | -1.941% | 28.141% |
Comments by Saftman for this prediction
In the thread AbbVie Inc. diskutieren
Saftman hat das Wertpapier AbbVie Inc. in seinem Wikifolio Langfristige Aufwärtstrends gekauft.
In the thread Trading AbbVie Inc.
Die von Saftman gewählte maximale Laufzeit wurde überschritten